Abstract |
The therapeutic effects of orally administered menogaril, a semisynthetic analog of the anthracycline antibiotic nogalamycin, were studied on a panel of human stomach and breast cancer xenografts. The maximum tolerated dose (200 mg/kg) of menogaril was administered 3 times every 4 days and its growth-inhibitory effects on subcutaneously implanted tumors in nude mice were evaluated. Menogaril significantly retarded the growth of 3 out of 7 stomach cancers, SC-2, SC-9 and 4-1ST, and 3 out of 4 breast cancers, H-31, MC-2 and MX-1, with overall response rates of 43 and 75% for stomach and breast cancers, respectively. Some of these relatively responsive cancers were also treated by daily oral administration for 5 consecutive days, but the anticancer effects of the intermittent administration seemed to be better. These results suggest that menogaril may be effective against stomach and breast cancers when orally administered.
|
Authors | M Inaba, S Sato, T Yamori, T Tashiro, Y Ohnishi, K Maruo, Y Ueyama, T Tsuruo |
Journal | Anticancer research
(Anticancer Res)
1992 Nov-Dec
Vol. 12
Issue 6B
Pg. 1953-6
ISSN: 0250-7005 [Print] Greece |
PMID | 1295442
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Administration, Oral
- Animals
- Breast Neoplasms
(drug therapy, pathology)
- Female
- Humans
- Menogaril
(administration & dosage, therapeutic use)
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Stomach Neoplasms
(drug therapy, pathology)
- Transplantation, Heterologous
- Tumor Cells, Cultured
|